Cargando…
Repositioned Drugs for Chagas Disease Unveiled via Structure-Based Drug Repositioning
Chagas disease, caused by the parasite Trypanosoma cruzi, affects millions of people in South America. The current treatments are limited, have severe side effects, and are only partially effective. Drug repositioning, defined as finding new indications for already approved drugs, has the potential...
Autores principales: | Adasme, Melissa F., Bolz, Sarah Naomi, Adelmann, Lauren, Salentin, Sebastian, Haupt, V. Joachim, Moreno-Rodríguez, Adriana, Nogueda-Torres, Benjamín, Castillo-Campos, Verónica, Yepez-Mulia, Lilián, De Fuentes-Vicente, José A., Rivera, Gildardo, Schroeder, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699892/ https://www.ncbi.nlm.nih.gov/pubmed/33233837 http://dx.doi.org/10.3390/ijms21228809 |
Ejemplares similares
-
Computational Drug Repositioning for Chagas Disease Using Protein-Ligand Interaction Profiling
por: Juárez-Saldivar, Alfredo, et al.
Publicado: (2020) -
Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs
por: Parisi, Daniele, et al.
Publicado: (2020) -
From malaria to cancer: Computational drug repositioning of amodiaquine using PLIP interaction patterns
por: Salentin, Sebastian, et al.
Publicado: (2017) -
Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor
por: Adasme, Melissa F., et al.
Publicado: (2020) -
Drug Repositioning for COVID-19
por: Benavides-Cordoba, Vicente
Publicado: (2020)